Metastatic Differentiated Thyroid Cancer

Drug	Drug Name	Drug Description
DB08875	Cabozantinib	A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.

Drug	Drug Name	Target	Type
DB08875	Cabozantinib	Cytochrome P450 3A4	enzyme
DB08875	Cabozantinib	Cytochrome P450 2C9	enzyme
DB08875	Cabozantinib	Hepatocyte growth factor receptor	target
DB08875	Cabozantinib	Vascular endothelial growth factor receptor 2	target
DB08875	Cabozantinib	Proto-oncogene tyrosine-protein kinase receptor Ret	target
DB08875	Cabozantinib	Cytochrome P450 2C8	enzyme

Drug	Drug Name	Phase	Status	Count
DB00945	Acetylsalicylic acid	2	Completed	1
DB09293	Iodide I-131	2	Recruiting	1
DB00398	Sorafenib	2	Completed	1